Intra-Cellular Therapies ITCI reported its Q2 earnings results on Tuesday, August 9, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
Intra-Cellular Therapies missed estimated earnings by 21.05%, reporting an EPS of $-0.92 versus an estimate of $-0.76.
Revenue was up $35.53 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.14 which was followed by a 0.26% increase in the share price the next day.
Here's a look at Intra-Cellular Therapies's past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.92 | -1 | -0.92 | -0.80 |
| EPS Actual | -0.78 | -1.05 | -0.95 | -0.85 |
| Revenue Estimate | 33.65M | 25.37M | 22.12M | 19.44M |
| Revenue Actual | 35.00M | 25.67M | 22.21M | 20.05M |
To track all earnings releases for Intra-Cellular Therapies visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
